Reports on HIV/AIDS: 1990

NOVEMBER 30, 1990, MMWR, Vol. 39, RR-16 [inclusive page numbers]
with AIDS receive the diagnosis and die in the same month and that the remaining
87% have an exponential distribution of survival, with median survival of 11 months
for patients diagnosed through December 1985, 14 months for patients diagnosed in
January 1986-June 1987, and 16.3-18.7 months for patients diagnosed after that date.
This change in survival corresponds to assumptions that patients taking zidovudine
have a 35% reduction in the risk of death and that 40%-75% of persons with AIDS are
being treated. Total deaths associated with HIV infection were estimated as 1.33 x the
number of deaths among persons with reported diagnoses of AIDS, reflecting the
estimate that approximately 75% of all HIV-associated deaths are deaths of persons
who have reported AIDS diagnoses (1/0.75 = 1.33).
References
Al. Karon JM, Devine OJ, Morgan WM. Predicting AIDS incidence by extrapolating from recent
trends. In: Mathematical and Statistical Approaches to AIDS Epidemiology, C. CastilloChavez, ed. Lecture Notes in Biomathematics, vol. 83, Berlin; Springer Verlag, 1989:58-88.
A2. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Amer
Statist Assoc 1979;74:829-36.
A3. Brookmeyer R, Goedert JJ. Censoring in an epidemic with an application to hemophiliaassociated AIDS. Biometrics 1989;45:325-35.
A4. Brookmeyer R, Gail MH. A method for obtaining short-term projections and lower bounds
on the size of the AIDS epidemic. J Amer Statist Assoc 1988;83:301-8.
A5. Brookmeyer R, Damiano A. Statistical methods for short-term projections of AIDS incidence.
Stat Med 1989;8:23-34.
A6. Hyman JM, Stanley EA. Using mathematical models to understand the AIDS epidemic.
Math Biosci 1988;90:415-73.
A7. Hay JW. Projecting the medical costs of HIV/AIDS: an update with focus on epidemiology.
In: New Perspectives on HIV-Related Illness: Progress in Health Services Research -
Conference Proceedings. National Center for Health Services Research, Pub. No. DHHS
(PHS) 89-3449. Rockville, MD: September, 1989:84-97.
A8. Hay JW, Wolak FA. Bootstrapping HIV/AIDS projection models: back-calculation with linear
inequality-constrained regression. Working Paper in Economics E-90-5, Hoover Institution,
Stanford, California, 1990.
A9. Auger I, Thomas P, De Gruttola V, et al. Incubation periods for paediatric AIDS patients.
Nature 1988;336:575-7.
A10. Brookmeyer R, Liao J. Statistical modelling of the AIDS epidemic for forecasting health
care needs. Biometrics 1990;46:1151-63.
All. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human
immunodeficiency virus infection: a controlled trial in persons with fewer than 500
CD4-positive cells per cubic millimeter. N EngI J Med 1990;322:941-9.
A12. Stoneburner RL, Des Jarlais DC, Benezra D, et al. A larger spectrum of severe HIV-1 related
disease in intravenous drug users in New York City. Science 1988;242:916-9.
A13. Buehler JW, Devine OJ, Berkelman RL, Chevarley FM. Impact of the human immunodeficiency virus epidemic on mortality trends in young men, United States. Am J Public Health
1990;80:1080-6.
A14. CDC. HIV/AIDS Surveillance Report, October 1990: Centers for Disease Control, Atlanta,
Georgia: pp. 1-18.
A15. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA
1990;263:402-6.
A16. Harris JE. Improved short-term survival from AIDS among patients initially diagnosed with
Pneumocystis carinii pneumonia, 1984 through 1987. JAMA 1990;263:397-401.

172